Acorda Therapeutics, Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$23.5M
Doctors Paid
7,562
Transactions
52,935
2024 Total
$192,543
Payment Breakdown by Category
Research$12.6M (53.6%)
Consulting$2.5M (10.6%)
Travel$495,101 (2.1%)
Food & Beverage$460,255 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.6M | 2,493 | 53.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7.4M | 31,047 | 31.6% |
| Consulting Fee | $2.5M | 483 | 10.6% |
| Travel and Lodging | $495,101 | 2,263 | 2.1% |
| Food and Beverage | $460,255 | 16,510 | 2.0% |
| Grant | $10,160 | 22 | 0.0% |
| Education | $698.61 | 117 | 0.0% |
Payments by Type
Research
$12.6M
2,493 transactions
General
$10.9M
50,442 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Prkinsons Patients Using Levodopa TOZPD | $2.7M | 0 | 293 |
| CDS - Acorda Therapeutics - Post Stroke Modality - Ampyra | $2.3M | 11 | 787 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinsons Disease Experiencing End-of-Dose Wearing-Off | $2.1M | 0 | 154 |
| Twelve Month Safety and Efficacy Study of CVT-301 In Parkinsons Disease Patients With OFF Episodes | $1.4M | 0 | 636 |
| An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse | $755,114 | 0 | 155 |
| A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant | $411,512 | 0 | 28 |
| A Phase 1 study to investigate the pharmacokinetics, safety, and tolerability of CVT-301 inhalation powder in health Japanese and Causasian subjects. | $408,514 | 0 | 3 |
| TOZ-CL05 | $250,964 | 0 | 23 |
| CVT-301-012 | $249,203 | 0 | 8 |
| SYN120 CL03154 | $246,949 | 0 | 36 |
| Efficacy and Safety Study of CVT-301 In Parkinsons Disease Patients With OFF Episodes SPAN-PD | $243,521 | 0 | 104 |
| TOZ-CL06 | $231,892 | 0 | 34 |
| CVT-301-013 | $228,518 | 0 | 2 |
| Pharmacokinetic Study of CVT-301 Levodopa Inhalation Powder | $179,188 | 0 | 20 |
| A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 Levodopa Inhalation Powder | $157,302 | 0 | 25 |
| Randomized Safety Study of CVT-301 Compared to an Observational Control Group | $109,412 | 0 | 50 |
| A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant | $107,509 | 0 | 31 |
| SYN120CL03 | $85,063 | 0 | 12 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off | $69,963 | 0 | 6 |
| CVT-427 TRIP-PK-1041 | $59,372 | 1 | 5 |
| SYN120-CL03 | $54,339 | 0 | 13 |
| SYN-120 | $45,709 | 0 | 1 |
| A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 Levodopa Inhalation Powder in Parkinsons Disease Patients With Motor Response Fluctuations OFF Phenomena | $29,636 | 0 | 5 |
| SYN120 a Dual 5-HT65-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinsons Disease Dementia SYNAPSE | $26,353 | 0 | 9 |
| SYN-120CL03 | $23,069 | 0 | 2 |
| A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 Levodopa Inhalation Powder in Parkinson's Disease Patients With Motor Response Fluctuations OFF Phenomena | $17,589 | 1 | 12 |
| SYN120 CL03 | $15,659 | 0 | 4 |
| CVT-301-009 | $13,156 | 0 | 5 |
| CVT-301 | $11,312 | 1 | 11 |
| SYN-120-CL03 | $9,753 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Prof. Gurkirpal Sehgal, Md, MD | Gastroenterology | Woodside, CA | $674,824 | $0 |
| Katherine Smith, Md, MD | Pediatrics | Raleigh, NC | $329,190 | $0 |
| Matthew Stern, Md, MD | Neurology | Philadelphia, PA | $306,751 | $0 |
| Dr. Stuart Isaacson, Md, MD | Neurology | Boca Raton, FL | $268,155 | $0 |
| Indu Subramanian, Md, MD | Neurology | Los Angeles, CA | $179,039 | $0 |
| Khashayar Dashtipour, M.d, M.D | Neurology | Loma Linda, CA | $170,497 | $0 |
| Unknown Provider | — | — | $167,277 | $0 |
| Karl Kieburtz, Md, MD | Neurology | Rochester, NY | $159,000 | $0 |
| Dr. Aasef Shaikh, M.d, M.D | Neurology | Cleveland, OH | $157,247 | $0 |
| Ramsey Falconer, M.d, M.D | Neurology | Alexandria, VA | $148,211 | $0 |
| Dr. Ramon Rodriguez-Cruz, Md, MD | Neurology | Orlando, FL | $144,325 | $0 |
| Dr. Peter Lewitt, M.d, M.D | Neurology | West Bloomfield, MI | $128,361 | $0 |
| Dr. Daniel Kremens, M.d., J.d, M.D., J.D | Neurology | Philadelphia, PA | $128,302 | $0 |
| Aaron Ellenbogen, D.o, D.O | Neurology | Farmington Hills, MI | $126,956 | $0 |
| Dr. Yasar Torres-Yaghi, M.d, M.D | Neurology | Washington, DC | $121,673 | $0 |
| Dr. Jennifer Durphy, M.d, M.D | Neurology | Albany, NY | $115,893 | $0 |
| Dr. Rajeev Kumar, Md, MD | Neurology | Englewood, CO | $115,205 | $0 |
| Dr. David Kreitzman, M.d, M.D | Neurology | Commack, NY | $111,868 | $0 |
| William Ondo, M.d, M.D | Neurology | Houston, TX | $108,658 | $0 |
| Dr. Laxman Bahroo, D.o,, D.O, | Neurology | Washington, DC | $108,298 | $0 |
| Robert Hauser, Md, MD | Neurology | Tampa, FL | $107,974 | $0 |
| Dr. Salima Brillman, Md, MD | Psychiatry | Sunnyvale, CA | $98,647 | $0 |
| Dr. Sandeep Thakkar, D.o, D.O | Neurology | Irvine, CA | $95,138 | $0 |
| Dr. Diego Torres-Russotto, Md, MD | Neurology | Miami, FL | $91,130 | $0 |
| Dr. Cherian Karunapuzha, Md, MD | Neurology | Oklahoma City, OK | $89,680 | $0 |
About Acorda Therapeutics, Inc
Acorda Therapeutics, Inc has made $23.5M in payments to 7,562 healthcare providers, recorded across 52,935 transactions in the CMS Open Payments database. In 2024, the company paid $192,543. The top product by payment volume is INBRIJA ($6.3M).
Payments were distributed across 149 medical specialties. The top specialty by payment amount is Neurology ($7.9M to 3,937 doctors).
Payment categories include: Food & Beverage ($460,255), Consulting ($2.5M), Research ($12.6M), Travel & Lodging ($495,101).
Acorda Therapeutics, Inc is associated with 2 products in the CMS Open Payments database.